Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUIP: Qsymia in Severe Obesity
NCT00554216Phase 3Completed
- Sponsor
- VIVUS
- Start
- Nov 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phentermine + topiramate in obesity (3 arms), sponsored by VIVUS. Primary endpoints: Percent Weight Loss From Baseline to Week 56 and Percentage of Subjects With at Least 5% Weight Loss at Week 56. Started Nov 2007; status: completed.
02
Drugs
phentermine + topiramate
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00554216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554216.